Herpesvirus infections: myths and realities

Authors

  • V Makarenko Kharkov Medical Academy of Postgraduate Education,

Keywords:

herpesvirus infection, etiology, clinical features in children, diagnostics

Abstract

Herpesvirus infections (HVI) is known for more than two millennia, and its main symptoms described by Hippocrates more. But our time HVI remains mysterious and before the end of the unknown. Among the issues are not sufficiently clarified latency of infection and persistence of herpes viruses, the causes of the frequent occurrence of the disease in the form of subclinical forms, high infection rate of the world population, and others. Note that virologists and clinicians are showing in the last 20 years to the HVI, is associated with a variety of ever-increasing role Herpesviridae in infectious pathology of human and social importance of diseases caused by them. It is now known 8 herpesviruses pathogenic for humans. Because of the difference in a number of biological properties, the nature of replication in cell cultures, the clinical picture and the pathogenesis of diseases caused by all herpesviruses are distributed according to the recommendations of the International Committee on Taxonomy of Viruses, in three subfamilies (α, β, γ). Activators of herpes simplex virus can be endogenous and exogenous factors: reduction of immunoreactivity of the organism (immunodeficiency, interferon failure), physical and emotional stress, overheating or overcooling, hormonal disorders, ultraviolet irradiation, corticosteroids treatment, cytotoxic drugs. It is important to understand that the HVI is a disease of the whole body with lesions in varying degrees, all organs and systems (immune, hematopoietic, lymphatic, CNS), which is responsible for the homeostasis of the human body. These data give reason to believe HVI systemic disease, mainly affecting a particular organ. However, more is still not widely used etiopathogenetical and "topical" diagnosis, indicating the loss of any one body. Due to the fact that the clinical forms of HVI are characterized by marked polymorphism, the timely establishment of the etiologic diagnosis is a difficult task and is based on the use of specific molecular genetic, virological, immunological and serological methods. It is generally recognized that the treatment of patients with herpes is quite a challenge for practitioners, it requires professional skills in these patients, a differentiated approach depending on the clinical form of the disease, as well as the condition of the patient's immune system. Data of own observations have shown that HVI retains its relevance due to the high infection and morbidity in children (more than 30% of all children referred for advice); the need to use complex laboratory studies; the possibility of persistent currents without clinical manifestations and course of active viral replication, requiring the appointment of antiviral drugs.
Conclusions. In order to provide quality health care to patients with HVI requires knowledge of modern principles of diagnosis and therapy. Ability to herpesvirus latency and reactivation of the development of manifest forms of the disease necessitates the development of control strategies for the HVI and more efficient use of suppressive antiviral therapy and vaccine prevention.

References

Lanari M. Congenital infection with human herpesvirus 6 variant B associated with neonatal seizures and poor neurological outcome [Text]/ M. Lanari, I. Papa, V.Venturi, T.Lazzarotto et al. // J Med Virol. 2003 Aug; 70(4): 628-632.

Griffiths P.D. Progress with diagnostic tests and vaccines for alpha-herpesviruses [Text]/ P. D. Griffiths, A. Volpi //Recommendations from the IHMF Management Strategies Workshop and 5th Annual Meeting.-1997.-p.1–68.

Malkin J-E. The continuing spread of HSVinfection. Worldwide epidemiology [Text]/ J-E. Malkin //Herpes.-2005.-12:3-p.77.

Vaughan P.J. DNA-binding protein associated with herpes simplex virus DNA polymerase [Text]/ P.J. Vaughan, D.J. Purifoy, K.L. Powell // J. Virol. 1985. Vol.53. P.501-508.

Wildy P. Portraits of viruses. Herpes virus [Text]/ P. Wildy // Intervirology. 1986. Vol.25. P.117-140.

Herpes. Role in human pathology. Antiviral drugs [Text] // ed. L. A. Panchenko. - Kharkov: Planet-Print, 2014. – 204 p.

Whitley, R. J. Herpes Zoster: Risk Categories for Persistent Pain [Text] /R. J. Whitley et al.// Journ. of Infectious Diseases. — 2007. — Vol. 179. — P.9 — 15.

Fowler K. W. The outcome of congenital cytomegalic virus infection in relation to maternal antibody status [Text]/ K. W. Fowler, S. Stagno, R. F. Pass et al. // N Engl J Med; 1992; 326: 663-667.

Hall C. B. Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7) [Text] / C. B. Hall, M. T. Caserta, K. C. Schnabel, C. Boettrich et al. //J Pediatr. 2004 Oct; 145(4): 472-477.

Whitley R. Neonatal herpes simplex virus infection [Text]/ R. Whitley // Curr Opin Infect Dis. 2004 Jun; 17(3): 243-246.

Kazmirchuk V. V. Herpetic infection in the structure of the critical states in infectious diseases among children [Text]/ V. V. Kazmirchuk //: Authoref. dis. сand. med. sciences. Kiev, 2000. - 18 p.

Istaas A. S. Surveillance for congenital cytomegalovirus disease: A Report from the National Cytomegalovirus Disease Registry [Text]/ A. S. Istaas, G. J.Demmler, J. G. Dobbins et al. //Clin Inf Dis. 1995. 20. С. 665-670.

Noyola D. E. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection [Text]/ D. E. Noyola, G. J. Demmler, C. T. Nelson et al. //J. Pediatr. 2001; 38; 3: 325-331.

Jackson, J.L. The effect of treating Herpes zoster with oral acyclovir in preventing posttherapeutic neuralgia. A metaCanalysis [Text]/ J.L. Jackson, R. Gibbons, G. Meyer et al. // Arch. Intern. Med. 2007. Vol . 157. P.909E912.

Fields Virology, 5 th, edn. [Text]/ D.M. Knipe, P.M. How, D.E. Griffin et al (eds) // – 2007. – 3177 p.

Sandström E. The increasing importance of cytomegalovirus, Epstein-Barr virus and the human Herpesviruses types 6, 7 and 8 [Text]/ E. Sandström, R.J. Whitley //Recommendations from the IHMF Management Strategies Workshop and 3rd Annual meeting.-1995.-p.1–29.

Management of varicella zoster virus infection and the clinical implications of heresvirus latency.Building international congress. IHMF 1995; 37.

Whitley, R. J. Herpes Zoster: Risk Categories for Persistent Pain [Text]/R. J. Whitley et al.// Journ. of Infectious Diseases. — 2007. — Vol. 179. — P.9 — 15.

Infectious Disease of the Fetus and Newborn Infant. [Text] /Remington J. S., Klein J. O., eds.,// 5th ed., Philadelphia, PA: WB Saunders Co; 2001: 389-424.

Liberek A. Cytomegalovirus disease in neonates and infants - clinical presentation, diagnostic and therapeutic problems - own experience [Text]/ A. Liberek, M. Rytlewska, A. Szlagatys - Sidorkiewicz et al. //Med Sci Monit. 2002; 8 (12): 815-820.

Numazaki K. Immunological evaluation and clinical aspects of children with congenital cytomegalovirus infection [Text]/ K. Numazaki, T.Fujikawa, H. Asanuma //Congenit Anom (Kyoto). 2002 Sep; 42(3): 181-186.

Mahy B.W.J. and M.H.V. van Regenmortel Encyclopedia of Virology. – 3th, end. – 2008. – 3233 p.

Ashley R.L. Premarket evaluation of a commercial glycoprotein G –based enzyme immunoassay for Herpes simplex virus type-specific antibodies [Text]/ R.L. Ashley, L. Wu, J.W. Piscering et al. //J. Clin. Microbiol.1998;36:294–295.

Whitley R. J. Neonatal HSV-infections: a role of immunoglobulins in disease prevention and therapy [Text]/ R. J. Whitley // Pediatric Infections Disease Journal. 13(15): 432–8, 1994 May.

Kimberlin D.W. Herpes Simplex Virus Meningitis and Encephalitis in Neonates [Text]/ D.W. Kimberlin //Herpes.-2004.-N11.Suppl.2.-p.65A-76A.

Kimberlin D.W. Neonatal HSVinfections: the Global Picture [Text]/ D.W. Kimberlin //Herpes.-2004.-11:2-p.31–32.

John, W. VaricellaEZoster Virus: Atypical Presentations and Unusual Complications [Text]/ W. John, Jr Gnann // Journ. of Infectious Diseases. 2006. Vol.186. - P.91 - 98.

Sandström E. Genital and orofacial Herpes simplex virus infections — clinical implications of latency [Text]/ E. Sandström, R. J. Whitley //Recommendations from the IHMF Management Strategies Workshop and 6th Annual meeting.-1998.-p.1–36.

Walf A. Frequency of HSV shedding as measured by PCR[Text]/ A. Walf //Herpes.- 2005.-12:3/-p.77.

Spangler J. G. Uses and safety of acyclovir in pregnancy [Text]/ J. G. Spangler, J.K. Kirk, M.P. Knudson //Journal of Family Practice. 38(2): 186–91, 1994 Feb.

Perry C.M. Famcyclovir: A review of its pharmacological properties and therapeutic efficacy in Herpes virus infections [Text]/ C.M. Perry, A. J. Wagstaff //Drugs.50 (2): 396–415,1995 Aug.

Mindel A. Genital herpes-the “forgotten epidemic” [Text]/ A. Mindel //Herpes. - 1994. - V.1.- N2.-p.39–48.

Prober C.G. Preventing neonatal herpes [Text]/ C.G. Prober, J.A. Kolhanijan // N. Engl. J. Med.-1992.-327,9 –P. 647–648.

How to Cite

Makarenko, V. (2020). Herpesvirus infections: myths and realities. Annals of Mechnikov’s Institute, (1), 8–13. Retrieved from https://journals.uran.ua/ami/article/view/192112

Issue

Section

Research Articles